HomeInsightsResults

Shilpa Medicare Ltd Quarterly Result

Shilpa Medicare Ltd Quarterly Result

stocks purchased

₹ 2.6 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

28.2 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Shilpa Medicare Ltd

NSE: SHILPAMED

Net Profit

₹ 17.94

Last updated on: Nov 23, 2024

Key Highlights

  • The revenue of Shilpa Medicare Ltd for the Sep '24 is ₹ 348.79 crore as compare to the Jun '24 revenue of ₹ 301.95 crore. This represent the growth of 15.5125%.
  • The ebitda of Shilpa Medicare Ltd for the Sep '24 is ₹ 90.61 crore as compare to the Jun '24 ebitda of ₹ 79.52 crore. This represent the growth of 13.946182%.
  • The net profit of Shilpa Medicare Ltd for the Sep '24 is ₹ 17.94 crore as compare to the Jun '24 net profit of ₹ 14.06 crore. This represent the growth of 27.596016%.

Results Analysis

Market Price of Shilpa Medicare Ltd

1M

1Y

3Y

5Y

Monitoring Shilpa Medicare Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024911
21 Nov 2024935.8
19 Nov 2024879.9
18 Nov 2024863.4
14 Nov 2024872.9
13 Nov 2024824.75
12 Nov 2024878.05
11 Nov 2024893.2
08 Nov 2024852.7
07 Nov 2024843.4

Historical Revenue of Shilpa Medicare Ltd

No data available

* All values are in crore

Historical EBITDA of Shilpa Medicare Ltd

No data available

* All values are in crore

Historical Net Profit of Shilpa Medicare Ltd

No data available

* All values are in crore

Shilpa Medicare Ltd News Hub

News

Shilpa Medicare spurts on European regulator nod for Octreotide & Nifedipine

Octreotide, a synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid-p...

Read more

19 Nov 202411:24

News

Shilpa Medicare rallies after robust Q2 results

Profit before tax (PBT) surged 300.98% to Rs 36.77 crore in Q2 FY25 over Q2 FY24. EBITDA j...

Read more

14 Nov 202410:39

News

Shilpa Medicare update on its CDMO partner - Unicycive Therapeutics

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) has announced that the U.S. Food and Drug Admi...

Read more

12 Nov 202415:02

News

Shilpa Medicare schedules board meeting

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 13 Novembe...

Read more

04 Nov 202418:42

News

Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility

In a regulatory filing made during market hours today, the company informed the company's ...

Read more

31 Oct 202413:43

News

Shilpa Medicare arm gets CEP from EDQM for Desmopressin

Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid...

Read more

04 Oct 202408:40

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Shilpa Medicare Ltd Quarterly Result

What is the EPS of Shilpa Medicare Ltd stock?

The Earnings Per Share (EPS) of Shilpa Medicare Ltd is 5.87. An EPS is the amount of net income attributed to each share of a common stock.

How is Shilpa Medicare Ltd EPS calculated?

The EPS of Shilpa Medicare Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Shilpa Medicare Ltd report its EPS?

Shilpa Medicare Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Shilpa Medicare Ltd EPS?

Factors that influence the EPS of Shilpa Medicare Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Shilpa Medicare Ltd EPS growth indicate future performance?

Yes, consistent growth in Shilpa Medicare Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*